Tab Application Banner
  • Users Online: 2088
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2010  |  Volume : 5  |  Issue : 4  |  Page : 171-175

Pulse Pamidronate therapy in NSAID refractory ankylosing spondylitis. Is it effective?-An open label study


Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

Correspondence Address:
Skand Shukla
Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Objective: To assess the efficacy of pulse Pamidronate therapy in NSAID refractory ankylosing spondylitis (AS). Patients: Fifty two patients of ankylosing spondylitis (fulfilling modified New York criteria), refractory to NSAID and having active disease were enrolled. Active disease was defined as BASDAI ≥ 4 and/or early morning stiffness ≥ 45 minutes despite NSAID therapy. Intervention: Monthly intravenous Pamidronate infusions (60 mg) for a period of 6 months along with current NSAID. Primary outcome measure was improvement in BASDAI at the end of therapy. Secondary outcome mea- sures included improvement in BASDAI ≥ 25%, BASFI, metrology parameters, visual analogue scales for pain and global assessment of disease, ESR, CRP, MMP-3 and quality of life domains. Results: Out of 52 patients enrolled [47 men; mean age 36.2 years (range 22-53 years) and mean disease duration 7.2 years (3-25 years)], 47 patients completed the study. At 6 months, there were significant improvement in BAS- DAI (P < 0.005), BASFI (P < 0.005), pain (P < 0.005) and patient global assessment of disease (P < 0.005) and lateral flexion (P < 0.05). However, BASDAI ≥ 25% reduction was seen in 29.6% patients only. In addition, quality of life, HAQ and serological markers MMP-3, ESR and CRP were not significantly altered. Most common adverse effects included arthralgias and myalgias, 22.5% each, following initial infusions. There were five withdrawals; two defaults and one for hip joint replacement and two for asymptomatic rise in serum creatinine. Conclusion: Pamidronate has modest efficacy in improving the patient reported outcome variables in NSAID refractory AS.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed361    
    Printed4    
    Emailed0    
    PDF Downloaded67    
    Comments [Add]    

Recommend this journal